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Oncostatin M drives intestinal inflammation in mice and its abundance 1 
predicts response to tumor necrosis factor-neutralizing therapy in 2 
patients with inflammatory bowel disease 3 
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 2 
Abstract 1 
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), 2 
are complex chronic inflammatory conditions of the gastrointestinal tract that are driven by 3 
perturbed cytokine pathways. Anti-tumour necrosis factor-α (TNF) antibodies are a mainstay 4 
therapeutic approach for IBD. However, up to 40% of patients are non-responsive to anti-TNF 5 
agents, and identifying alternative therapeutic targets is a priority. Here we show that expression 6 
of the cytokine Oncostatin M (OSM) and its receptor (OSMR) is increased in the inflamed 7 
intestine of IBD patients compared to healthy controls, and correlates closely with 8 
histopathological disease severity. OSMR is expressed in non-hematopoietic, non-epithelial 9 
intestinal stromal cells, which respond to OSM by producing various pro-inflammatory factors 10 
including interleukin-6 (IL-6), the leukocyte adhesion factor ICAM-1, and chemokines that 11 
attract neutrophils, monocytes, and T cells. In an animal model of anti-TNF refractory intestinal 12 
inflammation, genetic deletion or pharmacological blockade of OSM significantly attenuates 13 
colitis. Furthermore, high pre-treatment OSM expression is strongly associated with failure of 14 
anti-TNF therapy based on analysis of over 200 IBD patients, including two cohorts from phase 3 15 
clinical trials of infliximab and golimumab. OSM is thus a potential biomarker and therapeutic 16 
target for IBD, with particular relevance for anti-TNF refractory patients. 17 
 18 
Introduction 19 
IBD is an etiologically complex inflammatory disorder, involving aspects of genetic 20 
predisposition, environmental triggers, microbial dysbiosis, and perturbation of immune 21 
homeostasis1-4. A crucial element of immune dysregulation in IBD is the inappropriate production 22 
of diverse pro-inflammatory cytokines, which orchestrate intestinal inflammation and constitute 23 
attractive targets for therapeutic development5,6. Indeed, blockade of TNF using monoclonal 24 
antibodies (anti-TNF therapy) is now firmly established as an effective therapeutic approach for 25 
IBD. Nevertheless, up to 40% of patients with IBD exhibit primary non-responsiveness to anti-26 
 3 
TNF therapy, and many patients who are initially responsive develop therapeutic resistance7,8. 1 
Various other cytokines have been targeted in clinical trials (including interferon (IFN)-γ, IL-6, 2 
and IL-17A) but their blockade has generally resulted in negligible efficacy or, in the case of IL-3 
17A, deleterious side effects5,9. Therefore, we sought to identify novel cytokines that could 4 
potentially serve as alternative therapeutic targets to TNF. In a large number of IBD patients, we 5 
identified OSM (Oncostatin M) as a highly expressed cytokine that is associated with anti-TNF 6 
resistant disease. Furthermore, OSM was found to promote intestinal pathology in an anti-TNF 7 
resistant mouse model of IBD. Intriguingly, OSM appears to promote intestinal inflammation by 8 
inducing chemokine, cytokine, and adhesion factor expression in gut-resident stromal cells, which 9 
express high levels of the OSM receptor-β (OSMR). 10 
 OSM is part of the IL-6 cytokine family, which shares gp130 as a receptor subunit10. 11 
Depending on the cell type, human OSM can induce signalling via the JAK-STAT pathway 12 
(including JAK1, JAK2, STAT1, STAT3, STAT5, and possibly STAT6), the 13 
phosphatidylinositol-3-kinase (PI3K)-Akt pathway, and mitogen activated protein kinase 14 
(MAPK) cascades via heterodimeric receptors comprised of gp130 and either OSMR or leukemia 15 
inhibitory factor receptor-β (LIFR)11,12. In contrast, mouse OSM is thought to mediate similar 16 
signal transduction mainly via gp130-OSMR heterodimers11,12. OSM supports diverse 17 
homeostatic processes, including liver repair, cardiac tissue remodeling, and 18 
osteoclastogenesis11,12. However, overproduction of OSM is thought to promote a variety of 19 
pathologies, including skin and lung inflammation, atherosclerosis, and several forms of 20 
cancer11,12. Interestingly, a single-nucleotide polymorphism in the human OSM locus is strongly 21 








OSM and OSMR are highly expressed in IBD 4 
To identify additional cytokines that may promote IBD pathogenesis, we analyzed cytokine 5 
mRNA expression in intestinal mucosal biopsies from previously published cohorts of patients 6 
with clinically active CD (n=162 CD versus n=42 non-IBD controls; RNA-seq data) or UC (n=74 7 
UC versus n=11 non-IBD controls; Affymetrix microarray data)16,17. 64 candidate cytokines with 8 
data available in both studies were examined. Of these, only 4 were significantly enriched in 9 
inflamed tissue in both cohorts compared to non-IBD controls: IL6, IL1A, IL1B, and OSM (Fig. 10 
1A, Supplementary Table 1). Among untreated paediatric patients with newly diagnosed CD16, 11 
we found OSM to be the most highly and consistently expressed cytokine relative to healthy 12 
control mucosa (Fig. 1b, Supplementary Table 1). Furthermore, OSM was particularly enriched 13 
in patients with deep mucosal ulcerations (Fig. 1c). While OSMR was similarly enriched in IBD 14 
mucosa, this was not true of LIFR or IL6ST (gp130) (Fig. 1c). 15 
 To validate our initial findings, we used quantitative real-time PCR (Q-PCR) to examine 16 
OSM and OSMR expression in freshly isolated biopsies from IBD patients and healthy controls 17 
who underwent routine endoscopy at the John Radcliffe Hospital (Oxford). This confirmed high 18 
expression of OSM and OSMR in tissue from IBD patients with active disease (Fig. 1d), and also 19 
revealed a close correlation between OSM/OSMR expression and histopathological disease 20 
severity (Fig. 1e). No difference in expression of either OSM or OSMR was observed in patients 21 
with CD or UC (Fig. 1f). Analysis of transcriptomic data from four different countries16-20 further 22 
confirmed that OSM and OSMR are consistently over-expressed in the intestinal mucosa of 23 
patients with active IBD (total control n=99, total IBD n=370; Supplementary Table 3). Neither 24 
OSM nor OSMR expression correlated with standard clinical parameters including gender, age at 25 
diagnosis, disease duration, serum c-reactive protein (CRP), peripheral blood leukocyte count, or 26 
 5 
treatment with pharmacological therapies; however, OSM and OSMR expression was increased in 1 
patients with IBD who required surgery, suggesting an association with treatment-refractory or 2 
complicated disease (Supplementary Fig. 1). 3 
 4 
Association of OSM expression with response to TNF-neutralizing therapy  5 
Hierarchical clustering of cytokine and chemokine expression in two IBD cohorts revealed that 6 
OSM is consistently associated with a discrete module of inflammatory mediators (Fig. 2a, 7 
Supplementary Fig. 2). Although molecular correlates of anti-TNF response have been reported 8 
previously, there are currently no clinically accepted predictive biomarkers of anti-TNF response 9 
for IBD18,21-23. We therefore asked whether the OSM-associated inflammatory module was 10 
associated with responsiveness to anti-TNF therapy. Among patients refractory to corticosteroids 11 
or other immunosuppressive therapies, unsupervised hierarchical clustering based on expression 12 
of OSM-associated module genes revealed that high module expression in pre-treatment biopsies 13 
was strongly associated with primary non-responsiveness to anti-TNF therapy (Fig. 1b, 14 
Supplementary Fig. 3a,b). Complete mucosal healing (based on endoscopic and histological 15 
criteria) following infliximab (Remicade) therapy was achieved by 69–85% of patients with low 16 
OSM module expression, but was observed in only 10–15% of those with high OSM module 17 
expression (Fig. 2c, Supplementary Fig. 3b). Notably, baseline expression of OSM and OSMR 18 
alone was strongly associated with poor primary response to infliximab in three different cohorts 19 
(Fig. 1d, Supplementary Fig. 3c,d)18,22,23. Indeed, at the whole transcriptome level, OSM was 20 
among the 20 most strongly expressed genes in anti-TNF refractory patients compared to anti-21 
TNF responders (Supplementary Table 4). Baseline OSM and OSMR expression was also 22 
elevated in patients who responded initially to infliximab but relapsed by week 30 post-treatment 23 
(Supplementary Fig. 3d). 24 
 The association between mucosal OSM expression and anti-TNF response was confirmed 25 
in two additional prospective patient cohorts from phase 3 clinical trials of moderate-to-severely 26 
 6 
active UC, one treated with intravenous infliximab (Fig. 2e–g), and the other treated with 1 
subcutaneous golimumab (Simponi), an alternative anti-TNF agent (Supplementary Fig. 3e–2 
i)24,25. Unlike the cohorts described above, these trials categorized patients into response groups 3 
on the basis of improvement in clinical Mayo scores. This allowed us to assess patients who 4 
achieved full remission following therapy, those who partially responded (an improvement in 5 
Mayo score, but with remaining disease activity), and those who were completely non-responsive 6 
to therapy. While OSM was clearly most highly expressed in the non-responsive group of 7 
infliximab-treated patients (Fig. 2f), it was significantly elevated in both non-responders and 8 
partial responders who received golimumab (Supplementary Fig. 3f). Although OSM correlates 9 
broadly with inflammation severity in the overall IBD population (Fig. 1e), OSM did not 10 
correlate substantially with disease severity in these clinical trial cohorts, which were comprised 11 
exclusively of patients with strong disease activity (Fig. 2g, Supplementary Fig. 3h). In 12 
addition, baseline disease activity and clinical biomarker expression in these trials was not 13 
significantly associated with treatment response (Fig. 2e, Supplementary Fig. 3e–g), suggesting 14 
that OSM measurement prior to therapy could yield useful prognostic information that cannot be 15 
obtained from conventional clinical assessment. Thus, analysis of five datasets (comprising 227 16 
patients) demonstrates that high baseline OSM expression in the intestinal mucosa is reproducibly 17 
associated with decreased responsiveness to anti-TNF therapy.  18 
 19 
Human intestinal stromal cells express high amounts of OSMR 20 
To gain insight into the role of OSM in the intestine, we conducted gene ontology network 21 
analysis of human IBD transcriptomic data using ClueGo26. Relative to TNF-high tissues (used as 22 
a control for generic inflammation), OSM-high and OSMR-high tissues were strongly enriched in 23 
genes related to leukocyte chemotaxis, extracellular matrix organization, and mesenchymal 24 
development, suggesting that OSM may influence non-hematopoietic stromal cells 25 
(Supplementary Fig. 4). Indeed, in mucosal biopsies from healthy donors and IBD patients 26 
 7 
analyzed using Q-PCR, OSMR expression correlated closely with the well established fibroblast 1 
products COL1A1 (collagen 1A1) and FAP (fibroblast activation protein-α), as well as the 2 
lymphoid tissue-like stromal markers PDPN (podoplanin/gp38) and ICAM1 (intercellular 3 
adhesion molecule-1; Fig. 3a) 27-32. All of these stromal genes were highly expressed in inflamed 4 
IBD specimens (Fig. 3b). Furthermore, stromal cells with strong PDPN expression were highly 5 
abundant in the colon lamina propria of patients with CD or UC (Fig. 3c).  6 
 Flow cytometry analysis of human intestinal mucosa revealed that OSMR is undetectable 7 
in epithelial and hematopoietic cells, expressed in low amounts by endothelial cells, and strongly 8 
expressed by the majority of CD45−EpCAM−CD31− stromal cells (Fig. 3d–f). In contrast, OSM 9 
was expressed by various hematopoietic populations in human intestinal mucosa, including CD4+ 10 
T cells and HLA-DR+ antigen presenting cells from both non-IBD controls and IBD patients 11 
(Supplementary Fig. 5a–d). Notably, OSMR was expressed more abundantly than the related 12 
IL-6 receptor by intestinal stromal cells from both non-IBD control and IBD patients 13 
(Supplementary Fig. 5g). Consistent with the high amounts of OSMR produced by stromal cells, 14 
OSM stimulation elicited phosphorylation of STAT3, STAT1, Akt, and ERK1/2 MAP kinases in 15 
CCD18Co cells (primary human intestinal stroma), whereas IL-6 triggered only STAT3 16 
phosphorylation (Fig. 3g). OSMR expression in different cell populations was equivalent in 17 
healthy control and IBD patients in terms of both the frequency of OSMRhigh cells (Fig. 3h) and 18 
OSMR expression intensity (Fig. 3i). This suggests that the increased OSMR expression in 19 
biopsies from IBD patients (Fig. 1) is due to an accumulation of OSMR-expressing stromal cells 20 
in the tissue, not increased OSMR expression per cell. Because stromal cells vastly outnumber 21 
endothelial cells in the intestine (Supplementary Fig. 5h) and are highly enriched in OSMR, 22 
stromal cells appear to be the dominant intestinal OSMR+ population. Intriguingly, OSMRhigh 23 
stromal cells co-expressed PDPN and ICAM-1, a phenotype that is similar to fibroblastic reticular 24 
cells (FRCs) in secondary lymphoid tissue (Fig. 3j)33. 25 
 26 
 8 
OSM promotes inflammatory activity in the intestinal stroma 1 
To assess the response of intestinal stromal cells to OSM, we treated CCD18Co cells with 2 
recombinant human OSM and used Q-PCR to profile expression of the OSM-associated 3 
inflammatory module (see Fig. 2a). Notably, half of the module members were directly induced 4 
by OSM stimulation, including IL6 and a functionally diverse set of chemokines (Fig. 4a). OSM 5 
also drove expression of ICAM-1 and PDPN, suggesting that it may enforce the phenotype of 6 
OSMRhigh stroma observed in vivo (Fig. 3j). The OSM response was strictly dependent on 7 
OSMR, but not LIFR (Supplementary Fig. 5i–j). 8 
 To determine if a similar OSM response can be detected in vivo, we used fluorescence 9 
activated cell sorting (FACS) to purify OSMRhigh and OSMRlow stromal cells from colon tissue of 10 
3 donors (Fig. 4b, Supplementary Fig. 5k). Q-PCR analysis of the purified cell populations 11 
revealed similar expression of classical fibroblast products including collagens, lumican, 12 
fibronectin, and CD90 (Fig. 4c, Supplementary Fig. 5l). However, relative to OSMRlow cells, 13 
OSMRhigh stroma expressed high amounts of several chemokines and cytokines including IL6, 14 
CCL2, CXCL1, and CXCL10, consistent with the gene induction profile observed in CCD18Co 15 
cells (Fig. 4c). This suggests that high OSMR expression identifies a more immunostimulatory 16 
subset of intestinal fibroblasts.  17 
 Because OSM is known synergize with other inflammatory cytokines (in breast cancer, 18 
for example), we asked whether combined OSM and TNF stimulation have synergistic effects in 19 
human intestinal stroma. Indeed, some genes (such as the CXCR3 ligands CXCL9/10/11) were 20 
synergistically induced in CCD18Co cells by combined OSM and TNF treatment, while others 21 
such as CCL2 were not (Fig. 4d, Supplementary Fig. 5m). Comparable responses were 22 
observed in primary ex vivo cultures of human colonic stromal cells (Fig. 4e, Supplementary 23 
Fig. 5n). Compared to stromal cells, HUVEC (human umbilical vein endothelial cells) were 24 
weakly responsive to OSM, consistent with lower endothelial expression of OSMR 25 
(Supplementary Fig. 5o–p). Intriguingly, stronger responses to OSM and TNF treatment were 26 
 9 
observed in primary stromal cultures from IBD patients compared to cultures from non-IBD 1 
controls (Fig. 4f). Although the mechanism underlying this difference is not clear, it may be 2 
related to a similar phenomenon observed in fibroblast-like synoviocytes from rheumatoid 3 
arthritis patients, which display imprinted hyperresponsivness to inflammatory stimuli, possibly 4 
due to mutations and/or epigenetic alterations34.  5 
 6 
The OSM-stromal axis is conserved in mice 7 
To explore the OSM-stromal axis in a relevant pre-clinical setting, we used a model IBD system 8 
driven by oral Helicobacter hepaticus infection and systemic IL-10 receptor blockade in wild 9 
type C57BL/6 mice (Hh+αIL-10R model, Fig. 5a)35,36. This causes T cell-dependent pathology 10 
that is resistant to anti-TNF therapy (Supplementary Fig. 6a)37. Furthermore, this model does 11 
not require signaling by IL-6, IL-1α, or IL-1β (Supplementary Fig. 6b–c). At peak disease 12 
severity, colon lamina propria leukocytes increased 10-fold in abundance (Fig. 5b). Osm and 13 
Osmr were highly expressed in the colons of colitic mice (Fig. 5c), and OSM protein was 14 
secreted in abundance by inflamed intestinal explants and detectable in fecal matter (Fig. 5d). 15 
The in vivo expression kinetics of OSM closely mirrored those of IL-6, IL-1β, and TNF, but 16 
differed substantially from IL-23, which is required at early time-points for induction of 17 
pathogenic T cell responses (Supplementary Fig. 6d)35,38.  18 
 Like humans, Osm displayed a hematopoietic expression pattern with relative enrichment 19 
in antigen presenting cells, based on Q-PCR analysis of FACS-sorted colon populations from 20 
healthy and colitic mice (Fig. 5e, Supplementary Fig. 6e). In contrast, Osmr expression was 21 
restricted to intestinal stromal cells in both healthy and inflamed animals (Fig. 5e). The colon 22 
stroma from inflamed mice also expressed high amounts of Il1b and Il6, suggesting that these 23 
cells adopt a pro-inflammatory state during colitis (Fig. 5e). Furthermore, the colon lamina 24 
propria of colitic mice was highly enriched in PDPN+ stromal cells, consistent with human IBD 25 
(Fig. 5f). To determine the location of OSMR-expressing cells in the intestine, we used 26 
 10 
RNAscope in situ hybridization. Osmr expression in healthy mouse colon tissue was detected in 1 
endothelial and stromal cells, the latter distributed widely within the lamina propria along the 2 
entire length of the crypt-villus axis, as well as within lymphoid clusters. No expression was 3 
observed in epithelial cells, and a similar expression pattern was observed in the ileum 4 
(Supplementary Fig. 7a). Consistent with the increased numbers of PDPN+ stromal cells and 5 
increased OSMR expression in inflamed colon tissue, the number of cells expressing Osmr was 6 
markedly increased in the lamina propria of colitic mice (Fig. 5g). Mouse colon stromal cells 7 
responded strongly to OSM in a manner similar to that of human stroma (Supplementary Fig. 7). 8 
In contrast, substantial OSM responsiveness was not observed in CD45+ leukocytes from mouse 9 
spleen or colon, or from mouse colonic epithelial organoids (Supplementary Fig. 7). Taken 10 
together, these data indicate that intestinal OSM biology of healthy and colitic mice is largely 11 
consistent with that seen in humans. 12 
 13 
OSM drives colitis in a pre-clinical model of anti-TNF refractory IBD 14 
To determine if OSM can influence anti-TNF refractory colitis, we compared OSM-deficient 15 
mice (Osm−/−) to co-housed wild type littermates using the Hh+αIL-10R model. At steady state, 16 
Osm−/− mice showed normal organ histology (Supplementary Fig. 8a), normal development of 17 
secondary and mucosal-associated lymphoid tissue (Supplementary Fig. 8b–d), a normal 18 
leukocyte repertoire in lymphoid and intestinal tissue, and normal frequencies of non-19 
hematopoietic cells in the colon (Supplementary Fig. 9). At peak disease severity, Osm−/− mice 20 
displayed reduced colon pathology based on colonoscopy and histological assessment compared 21 
to wild type controls, particularly with regard to severe disease features such as crypt abscess 22 
formation, submucosal inflammation, and edema (Fig. 6a–d). This was not due to differences in 23 
H. hepaticus colonization (Supplementary Fig. 9k). 24 
 Notably, Osm−/− colons displayed normal activation of chemokine and cytokine 25 
expression during the first week of colitis, as well as normal accumulation of leukocyte 26 
 11 
populations in the lamina propria (Fig. 6e, Supplementary Fig. 10a–d). However, this response 1 
was attenuated during week 2, in parallel with reduced accumulation of CD4+ T cells and 2 
granulocytes. Reduced proliferation of colonic CD4+ T cells (determined by Ki-67 staining) could 3 
not explain the differences in T cell abundance, and leukocyte accumulation in Osm−/− mesenteric 4 
lymph nodes was entirely normal (Supplementary Fig. 10e–f). This suggests that OSM has little 5 
influence on the early/acute phase of inflammation, but enhances inflammation at later time 6 
points by promoting stromal chemokine production and selective recruitment of CD4+ T cells and 7 
granulocytes. Indeed, to confirm that trafficking of Osm−/− leukocytes during acute inflammation 8 
is normal, we employed a model of skin inflammation that involves topical application of 9 
imiquimod (a toll-like receptor 7 agonist) to mouse ears over 6 days. Consistent with acute colon 10 
inflammation, Osm−/− and wild type littermates showed equivalent skin thickening and 11 
recruitment of monocytes, granulocytes, and T cells to skin and cervical lymph nodes 12 
(Supplementary Fig. 10g–l). Notably, in the Hh+αIL-10R colitis model, Osm−/− displayed 13 
reduced colon expression of the OSM-associated inflammatory module that is associated with 14 
anti-TNF resistance in humans (Supplementary Fig. 11a). 15 
 16 
OSM neutralization suppresses TNF-refractory colitis in mice  17 
To test the therapeutic utility of OSM, we treated wild type C57BL/6 mice with an Fc-tagged 18 
soluble OSMR-gp130 fusion protein (OR-Fc; Fig. 6f, Supplementary Fig. 11b)39 starting at day 19 
7 of the Hh+αIL-10R protocol, by which time colitis is readily detectable (Supplementary Fig. 20 
11c). Compared to commercially available polyclonal anti-OSM antibodies, the OR-Fc construct 21 
was more efficient at neutralizing OSM in an ex vivo mouse intestinal stromal culture assay 22 
(Supplementary Fig. 11b). OR-Fc treatment significantly reduced colitis severity compared to 23 
mock treatment (recombinant Fc protein), demonstrating the potential utility of OSM as a 24 
therapeutic target (Fig. 6g–h, Supplementary Fig. 11d). Consistent with Osm−/− mice, colonic 25 
 12 
expression of the clinically relevant OSM-associated inflammatory module during colitis was 1 
suppressed by therapeutic OSM blockade (Fig. 6i).  2 
 3 
Discussion 4 
IBD is a clinically challenging illness that strikes at a young age and causes life-long morbidity. 5 
The high rate of primary and acquired resistance to therapy makes IBD a significant area of 6 
unmet medical need, for which alternative therapeutic options and improved strategies for patient 7 
stratification are urgently required. Although cytokines are well known to mediate the 8 
dysregulated inflammatory state that characterizes IBD, few have proven useful as therapeutic 9 
targets5. The notable exception is TNF, neutralization of which has been profoundly successful 10 
for treating IBD. More recently, the IL-12/IL-23 neutralizing antibody ustekinumab has also 11 
shown clinical efficacy for CD40. Given that TNF, IL-12, and IL-23 are critical coordinators of 12 
immune responses, it is possible that antibodies targeting cytokines such as IFN-γ and IL-17A 13 
have failed to show efficacy because they do not hit key “master control” points in the cytokine 14 
hierarchy. Thus, identifying cytokines that control an array of downstream inflammatory 15 
processes may lead to effective targeted therapies for IBD. 16 
 In attempting to identify such cytokines, we discovered OSM to be consistently 17 
overexpressed in inflamed intestinal tissue of mice and humans. Hematopoietically derived OSM 18 
appears to mediate intestinal pathology by promoting inflammatory behavior in gut-resident 19 
stromal cells, which constitutes a novel system of leukocyte-stromal cell crosstalk that may have 20 
relevance in multiple mucosal tissues. OSM is expressed as part of a core inflammatory cytokine 21 
module including IL-6 and IL-1α/β, with effects that are distinct from the closely related IL-6 and 22 
synergistic with those of TNF. Whereas IL-23 is a critical trigger of bacterially driven colitis 23 
through its actions on T cells35,38, OSM may act as an inflammatory amplifier and driver of 24 
disease chronicity by promoting chemokine, cytokine, and adhesion factor production by 25 
intestinal stromal cells (Supplementary Fig. 11e). Whether OSM can influence tissue fibrosis via 26 
 13 
the stromal compartment remains to be determined. Intriguingly, OSM has been shown to bind 1 
extracellular matrix components (including collagen, laminin, and fibronectin) in a manner that 2 
protects it from proteolytic degradation and maintains biological activity for prolonged periods41. 3 
This system could amplify the biological effects of OSM in chronic inflammation by promoting 4 
accumulation of stable OSM protein, particularly in tissues with high amounts of extracellular 5 
matrix deposition. 6 
 The immunological importance of intestinal stromal cells is not well understood; while 7 
they can respond to microbial challenges and influence dendritic cell function under steady state 8 
conditions27,29, a critical inflammatory role for stromal cells in IBD has not been demonstrated28. 9 
Nevertheless, data from other inflammatory diseases such as rheumatoid arthritis support the 10 
hypothesis that stromal cells are active contributors to immune pathology34. The high frequency 11 
of fibrotic complications in CD is consistent with a pathological role for intestinal stromal cells. 12 
However, we found that lesional tissue from both CD and UC patients contains large numbers of 13 
PDPN+ stromal cells, despite UC not being strongly associated with fibrosis. Similarly, mice 14 
subjected to Hh+αIL-10R colitis show a substantial expansion of the intestinal stromal cell 15 
compartment in the absence of overt intestinal fibrosis. These observations highlight the 16 
possibility that intestinal stromal cells may contribute to inflammatory pathology in ways that 17 
extend beyond the simple deposition of extracellular matrix components. A major unanswered 18 
question regarding intestinal stromal cells is their ontogeny. Although the number of PDPN+ 19 
stromal cells clearly increases during intestinal inflammation in both mice and humans, it is 20 
unknown whether they arise from expansion of tissue-resident precursors, are recruited from 21 
elsewhere (e.g. via circulating precursors), or if they differentiate from a distinct cell type. 22 
Similarly, it is not known if OSMRhigh intestinal stromal cells represent a distinct mesenchymal 23 
lineage, or simply a particular state of activation or differentiation. 24 
 To assess the role of OSM in a preclinical model of IBD, we chose to employ the 25 
Hh+αIL-10R system. Although several murine models of IBD exist, we chose this system for the 26 
 14 
following reasons: (a) it does not require the use of genetically modified mice, which precludes 1 
the possibility of confounding developmental defects; (b) similar to current concepts of human 2 
IBD etiology, it requires dual triggers in the form of infection with the commensal pathobiont H. 3 
hepaticus and transient immune dysregulation via IL-10R blockade; (c) it is driven by a full 4 
spectrum of innate and adaptive immune processes, as occurs in human IBD patients; and (c) it is 5 
highly resistant to TNF blockade, making it ideal for investigating alternative drivers of colitis. 6 
Nevertheless, we have observed high expression of OSM in various additional mouse models of 7 
IBD, including chemically induced colitis and adoptive transfer of naïve CD4+ T cells to Rag−/− 8 
hosts, suggesting that OSM may be relevant beyond the Hh+αIL-10R model.  9 
 In addition to alternative therapeutic targets, IBD patients would benefit substantially 10 
from improved systems for predicting disease course and response to therapy. In the case of anti-11 
TNF therapy, no biomarkers are currently used for predictive purposes in standard clinical 12 
practice, and conventional clinical parameters are insufficient to predict therapeutic response21, 13 
meaning that caregivers are forced to make treatment decisions with little knowledge of whether a 14 
patient is likely to benefit. This places a large number of patients at unnecessary risk of 15 
developing anti-TNF related complications (e.g. infections)42,43, and inflates the economic burden 16 
of IBD care. However, with a robust degree of reproducibility, we observed that high OSM 17 
expression in intestinal mucosa is associated with a high risk of resistance to anti-TNF therapy. 18 
Our data thus highlight the potential for developing a robust assay—based on measuring 19 
expression of OSM or similar inflammatory factors—that could assist clinicians in determining 20 
whether to prescribe anti-TNF antibodies or explore alternative therapeutic options. 21 
 While OSM can influence tissue remodeling in organs such as the heart and liver44-48, 22 
Osm−/− mice are viable and healthy, suggesting that therapeutic blockade of OSM may cause 23 
minimal side effects. Indeed, OSM has been targeted for rheumatoid arthritis in phase I and II 24 
trials using a humanized anti-OSM monoclonal antibody (GSK315234)49. Little clinical efficacy 25 
was observed, but the drug was well tolerated, with a dose-related decrease in platelet counts 26 
 15 
being the most notable adverse effect (although all platelet counts remained within the normal 1 
reference range). This is consistent with a prior report that OSMR-deficient mice have modestly 2 
reduced platelet counts due to a reduction in bone marrow megakaryocyte progenitors50. Because 3 
Osm−/− mice have reduced nociception51 and OSM has been implicated in other inflammatory 4 
disorders such as psoriasis52-55 and arthritis56-59, which are common comorbidities of IBD60, it is 5 
tempting to speculate that OSM blockade could also be beneficial in managing extra-intestinal 6 
manifestations of IBD. OSM and OSMR are over-expressed in the vast majority of active IBD 7 
lesions, particularly in patients with anti-TNF resistant disease. OSM could therefore be a novel 8 
predictive biomarker and therapeutic target for this clinically challenging population, and clinical 9 
studies to evaluate this hypothesis are warranted.   10 
 16 
Methods  1 
Human samples and cell isolation. Intestinal pinch biopsies and surgical resection specimens 2 
were obtained from healthy donors or IBD patients attending the John Radcliffe Hospital 3 
Gastroenterology Unit (Oxford, UK). Biopsies were collected during routine endoscopy; 4 
resections were obtained from patients with IBD undergoing surgery for severe disease, 5 
chronically active disease, or complications of disease. Some non-IBD (non-inflamed) control 6 
specimens were obtained from normal regions of bowel adjacent to resected colorectal tumors. 7 
Informed, written consent was obtained from all donors. Human experimental protocols were 8 
approved by the NHS Research Ethics System (Reference numbers: 09/H0606/5 for IBD patients 9 
and 11/YH/0020 for controls). Tissues were prepared as previously described with minor 10 
modifications61. In brief, mucosa was dissected and washed in 1mM DTT (dithiothreitol) solution 11 
for 15 minutes at room temperature to remove mucus. Specimens were then washed three times in 12 
0.75 mM EDTA (ethylenediaminetetraacetic acid) to deplete epithelial crypts and digested 13 
overnight in 0.1 mg/ml collagenase A solution (Roche, UK). In some experiments, tissues were 14 
rapidly digested for 2 hours using 1 mg/ml collagenase A. For enrichment of mononuclear cells, 15 
digests were centrifuged for 30 minutes in a four-layer Percoll gradient and collected at the 16 
40%/60% interface. Stromal cells were collected at the 30%/40% interface or were analyzed in 17 
unfractionated samples. Stromal cells were cultured ex vivo as described27. All solutions used 18 
were supplemented with antibiotics (10,000 U/ml penicillin/streptomycin, 40 µg/ml gentamicin, 19 
10 µg/ml ciprofloxacin, and 0.025 µg/ml amphotericin B (Sigma Aldrich, UK)).  20 
 21 
Human mucosal inflammation scoring. Inflammation severity of human intestinal mucosa was 22 
classified by both endoscopic and histological criteria. Endoscopic classification was binarized 23 
into either inflamed or uninflamed categories based on assessment by the endoscopist. Where 24 
possible, matched biopsies were collected from both active lesions and macroscopically normal 25 
tissue at a distance from lesions. Endoscopic assessment was complemented by routine 26 
 17 
histopathological scoring by a gastrointestinal pathologist. Tissues were classified as quiescent 1 
(normal appearance), mildly inflamed, or severely inflamed. 2 
 3 
Analysis of transcriptomic data. Whole transcriptome data were downloaded from the Gene 4 
Expression Omnibus website (http://www.ncbi.nlm.nih.gov/geo/). Before analysis, data for genes 5 
of interest were median-normalized and log2 transformed. When genes in microarray data were 6 
represented by multiple probes, the probe with the greatest interquartile range was selected for 7 
analysis. The following publically available datasets were used in this study: GSE57945 (ileal 8 
biopsies from pediatric healthy controls and patients with newly diagnosed ileal CD, colonic CD, 9 
and UC)16, GSE59071 (UC)17, GSE4183 (undefined IBD)19, GSE38713 (UC)20, GSE16879 10 
(matched pre-therapeutic and post-therapeutic biopsies of infliximab treated UC and CD)18, and 11 
GSE12251 (UC before infliximab therapy)22. Unsupervised hierarchical clustering was performed 12 
using Gene Cluster 3.0, with complete linkage as the clustering method and Euclidean distance as 13 
the similarity metric.  14 
 In addition to the publically available datasets described above, we analyzed OSM 15 
expression using unpublished transcriptomic data from two groups of patients with moderate-to-16 
severe UC who were part of anti-TNF clinical trials (ClinicalTrials.gov Identifiers NCT00207688 17 
and NCT00487539). Patients from NCT00207688 were part of the ACT1/2 clinical trials of 18 
intravenous infliximab therapy24, and samples were collected and processed as described by 19 
Toedter et al (2011)23. Patients from NCT00487539 were part of the PURSUIT trial of 20 
subcutaneous golimumab therapy25. Briefly, mucosal colonic biopsies were collected at weeks 0 21 
and 6 during endoscopy from a sub-group of PURSUIT patients at 15 to 20 cm from the anal 22 
verge. Colon biopsies were also obtained from normal subjects who did not participate in the 23 
PURSUIT study to serve as controls. Informed consent was obtained from healthy individuals to 24 
undergo additional colonic biopsies for research purposes during colonoscopic procedures 25 
performed as part of routine clinical care (such as colorectal neoplasia screening or evaluation of 26 
 18 
gastrointestinal symptoms). The procedure verified that these individuals did not have 1 
inflammatory conditions of the gastrointestinal tract including IBD.. The normal colon samples 2 
were obtained from University of Pennsylvania School of Medicine (Philadelphia, PA) and 3 
University Hospital Gasthuisberg (Leuven, Belgium). Normal colon sample collection complied 4 
with the Principles of the Declaration of Helsinki and had ethics approval by the respective 5 
institutional review boards. Following collection, the patient and normal samples were preserved 6 
in RNAlater (Applied Biosystems, Foster City, CA). All biopsies were stored at –80 °C until 7 
RNA isolation was performed, which may have been up to 2 years following collection. RNA 8 
was isolated and hybridized to the GeneChip HT HG-U133+ PM Array (Affymetrix, Santa Clara, 9 
CA). Expression intensities were obtained from the Robust Multi-array Average (RMA) 10 
algorithm. The microarray data were pre-processed and normalized by Robust Multi-array 11 
Average using Array Studio software version 4.2 (OmicSoft Corp., St. Morrisville, NC). For 12 
analysis of OSM expression, Affymetrix probeset 230170_PM_at was used. 13 
 14 
Definition of response to anti-TNF therapy 15 
The criteria for determining primary responsiveness to anti-TNF therapy are described in the 16 
original reports of the GSE12251, GSE16879, and GSE23597 cohorts18,22,23. Briefly, patients with 17 
active IBD refractory to corticosteroids and/or immunosuppression underwent colonoscopy (with 18 
biopsy collection) within a week prior to anti-TNF therapy. For cohorts GSE12251 and 19 
GSE16879, response following treatment was defined as complete mucosal healing by both 20 
endoscopic and histological criteria. For GSE23597, treatment response was defined as a 21 
reduction from the baseline Mayo score of at least 3 points and at least 30%, with reduction in the 22 
rectal bleeding subscore of at least 1 point or an absolute rectal bleeding score of 0 or 1. For the 23 
ACT1/2 (NCT00207688)24 and PURSUIT (NCT00487539)25 clinical trials, response categories 24 
were defined as follows: clinical remission (post-treatment Mayo score of 0–2); partial clinical 25 
response (decrease from baseline Mayo score by ≥30% and ≥3 points, but post-treatment score 26 
 19 
≥3); or no clinical response (decrease from baseline Mayo score of <30% and/or <3 points). It 1 
should be noted that the definition of responsiveness in GSE23597 and the clinical trials was less 2 
robust than in the GSE12251 and GSE16879 discovery cohorts, where remission was defined 3 
strictly by the presence or absence of histologically evident inflammation following therapy. 4 
 5 
Mice. Wild type C57BL/6, C57BL/6.Osm−/−, and C57BL/6.Il1r1−/− mice were bred and 6 
maintained under specific pathogen free conditions in accredited animal facilities at the 7 
University of Oxford. C57BL/6.Osm−/− mice were acquired from the Jackson Laboratory (Maine, 8 
USA, stock # 022338) and C57BL/6.Il1r1−/− mice were a kind gift of Dr. Vincenzo Cerundolo. 9 
All procedures were conducted in accordance with the UK Scientific Procedures Act of 1986. 10 
Mice were negative for Helicobacter species and other known intestinal pathogens, were age and 11 
sex-matched, and more than 6 weeks old when first used. Both male and female mice were used 12 
in approximately equal proportions for all experiments. Mice were randomized to different 13 
treatments and all treatments were represented in a given cage of animals. In experiments 14 
involving Osm−/− mice, knockout animals and wild type littermate controls were co-housed. 15 
Experiments were replicated in two independent animal facilities within Oxford to control for 16 
differences in housing conditions. Minimum sample sizes for individual experiments were 17 
determined based not on a statistical method, but on experience with colitis models: n=3 for 18 
steady state animals and n=6 for animals given experimental colitis. 19 
 20 
Hh+αIL-10R colitis and in vivo treatments. Experimental colitis was induced as described35,36. 21 
Briefly, mice were fed 1x108 colony forming units (c.f.u.) of H. hepaticus by oral gavage 22 
delivered with a 22 G curved blunted needle on days 0 and 1 of the experiment. 1 mg of an 23 
IL-­‐‑10R blocking antibody (clone 1B1.2) was administered as an intraperitoneal injection once 24 
weekly starting at day 0. In this model, disease severity peaks after 14 to 21 days and slowly 25 
 20 
resolves thereafter. To neutralize OSM in vivo, mice were treated with a previously described 1 
OSM receptor fusion protein (OR-Fc)39. For increased in vivo stability, this construct was tagged 2 
with the Fc region of mouse IgG2A. OR-Fc was administered as a 150 µg intraperitoneal 3 
injection every 2 days (equivalent to approximately 6 mg/kg). Molar-equivalent doses of IgG2A-4 
Fc (manufactured under the same conditions as OR-Fc) were used as control treatments. Some 5 
mice were also treated with a TNF-neutralizing antibody (clone XT3.11, Bio X Cell, USA) at a 6 
total weekly intraperitoneal dose of 1 mg per animal. This dose was found to completely abrogate 7 
intestinal pathology in 129SvEv.Rag–/– mice infected with H. hepaticus (not shown). For 8 
experiments involving anti-IL6R treatment and C57BL/6.Il1r1−/− mice, anti-IL10R was injected 9 
once per week (starting at day 0) and animals were sacrificed after 4 weeks. Similarly, anti-IL6R 10 
(clone D7715A7) was administered once per week as a 1 mg intraperitoneal dose starting at day 11 
0. 12 
 13 
Scoring of mouse colitis. Colonoscopy to assess colitis severity was performed and scored 14 
according to the methods of Becker et al62. Histological assessment of colitis severity was 15 
performed as described63. Briefly, formalin-fixed paraffin-embedded cross-sections of proximal, 16 
middle, and distal colon were stained with hematoxylin and eosin and graded on a scale of 0 to 3 17 
for four parameters: epithelial hyperplasia and goblet cell depletion, leukocyte infiltration, area 18 
affected, and features of severe disease activity. Common severity features include crypt abscess 19 
formation, submucosal leukocyte infiltration, and interstitial edema. Scores for each criterion are 20 
added to give an overall score of 0 to 12 per colon section. Data from the three colon regions are 21 
then averaged to give an overall score. Scoring was conducted in a blinded fashion and confirmed 22 
by an independent blinded observer. Interobserver Pearson correlation coefficients ranged from 23 
0.90 to 0.95. 24 
 25 
 21 
Mouse colon tissue preparation and cell isolation. Mouse colons were washed with EDTA to 1 
remove epithelium and digested with collagenase VIII to liberate cell populations as described64. 2 
Tissue digests were separated by centrifugation on a 30%/40%/70% percoll gradient. Cells at the 3 
30%/40% interface were collected as the stroma/epithelium-enriched fraction, whilst cells at the 4 
40%/70% interface were collected as the lamina propria leukocyte enriched fraction. For ex vivo 5 
stromal culture, stromal fractions were plated and cultured as described36. 6 
 7 
Colon explant cultures. Mouse proximal colon segments (0.25 cm2) were cultured overnight in 8 
RPMI media with 10% fetal calf serum (FCS) and 10,000 U/ml penicillin/streptomycin. OSM 9 
was quantified in the supernatant by enzyme-linked immunosorbent assay (ELISA, R&D 10 
Systems, UK) and normalized to explant weight.  11 
 12 
Stimulation of stromal and endothelial cells. CCD18Co cells (primary human intestinal 13 
fibroblasts; ATCC, not currently listed as misidentified on the ICLAC database) and primary ex 14 
vivo stromal cultures were grown in humidified incubators with 5% CO2 at 37°C in DMEM 15 
media (Sigma) with 10% FCS and 2% human serum (Sigma). HUVEC cells (Gibco) were 16 
cultured as above in Medium 200 with low serum growth supplement (Gibco) according to 17 
manufacturer instructions. For cytokine stimulation experiments, unless otherwise indicated, all 18 
treatments were for two hours, and all cytokines were administered at a concentration of 10 19 
ng/ml. Cells were cultured for no more than 8 passages to avoid onset of senescence, phenotypic 20 
drift, and contamination (e.g. by mycoplasma). All cytokines were purchased from Peprotech. To 21 
knock down OSMR expression in CCD18Co cells, Accel SMARTpool siRNA was used 22 
following manufacturer instructions (GE Healthcare Dharmacon, USA), and cells were stimulated 23 
to test for OSM sensitivity after 72 hours of transfection. 24 
 25 
 22 
RNA extraction, cDNA synthesis, and qPCR. Tissues were disrupted using lysis beads and a 1 
homogenizer unit (Precellys, UK) in RLT buffer (Qiagen, UK). Sorted or cultured cells were 2 
lysed directly in RLT buffer and homogenized by pipetting. RNA was isolated using RNEasy 3 
Mini or Micro kits (Qiagen, UK) followed by reverse transcription using random primers 4 
(Applied Biosystems, UK). Quantitative PCR (qPCR) was performed using Taqman assays 5 
(Applied Biosystems) and PrecisionPlus Mastermix (Primer Design, UK) on a ViiA7 384-well 6 
real-time PCR detection system (Applied Biosystems). All expression levels were normalized to 7 
an internal house keeping (HK) gene (RPLP0 for human samples and Hprt for mouse samples) 8 
and calculated as 2^−(CTHK−CTgene).   9 
 10 
Flow cytometry and cell sorting. Mouse cells were stained with combinations of the following 11 
monoclonal antibodies according to manufacturer protocols: CD3-PE (UCH-T1), CD4-BV605 12 
(RM4-5), CD8-APC (53-6.7), CD11b-PerCP-Cy5.5 (M1/70), CD11c-efluor450 (N418), CD19-13 
biotin (6D5), CD31-BV605 (390), CD44-V500 (IM7), CD44-AF700 (IM7), CD45-BV650 (30-14 
F11), CD45-AF700 (30-F11), Foxp3-efluor450 (FJK-16s), PDPN-PE-Cy7 (8.1.1), Gr1-APC 15 
(RB6-8C5), ICAM1-PE (YN1/1.7.4), Ly6C-PE-Cy7 (HK1.4), MHCII-AF700 (M5/114.15.2), 16 
siglec-f-PE (E50-2440), and TCRβ-BV510 (H57-597). Human cells were stained with the 17 
following monoclonal antibodies: CD3-BV510 (OKT3), CD4-PE-Dazzle594 (RPA-T4), CD19-18 
BV650 (HIB19), CD31-BV605 (WM59), CD45-AF700 (HI30), CD45RA-PE-Cy7 (HI100), 19 
EpCAM-FITC (9C4), PDPN-AF647 (NC-08), HLA-DR-BV711 (L243), ICAM1-BV421 (HA58), 20 
OSM-APC (17022), OSMR-PE (AN-V2), TNF-efluor450 (MAb-11), IFN-γ-FITC (B27), and IL-21 
17A-PE (eBio64DEC17). All antibodies were from eBioscience (UK), Biolegend (UK), Becton 22 
Dickinson (UK), or R&D Systems (UK). Dead cells were excluded using efluor-780 fixable 23 
viability dye (eBioscience). Samples were acquired on FACS LSRFortessa and FACS LSRII flow 24 
cytometers (Becton Dickinson). Cell sorting was performed using a FACS ARIA III (Becton 25 
Dickinson). Data were analyzed using FlowJo (Tree Star, USA). For intracellular cytokine 26 
 23 
staining, cells were restimulated with PMA (5 ng/ml; Sigma-Aldrich), ionomycin (500 ng/ml; 1 
Sigma-Aldrich), and 5 µg/ml brefeldin A (Sigma-Aldrich). After 4 hours, cells were stained with 2 
fixable viability dye and surface markers, fixed with 2% formaldehyde (Merck, UK), and stained 3 
for intracellular cytokines in permeabilization buffer containing 0.05% saponin (Sigma-Aldrich). 4 
For staining Foxp3, cells were stained with fixable viability dye and surface markers prior to 5 
fixation and permeabilization using the Foxp3 staining buffer kit (eBioscience) according to 6 
manufacturer instructions.  7 
 8 
OSMR staining. To stain OSMR in human samples for flow cytometry analysis, cells were 9 
labeled with primary OSMR-PE antibody (clone AN-V2, 2 µg/ml) followed by three rounds of 10 
amplification with anti-PE-biotin antibody (clone PE001, 2.5 µg/ml (Biolegend, UK)), and 11 
streptavidin-PE (0.4 µg/ml (Biolegend, UK)). A separate cell sample was labeled with isotype 12 
control antibody (mouse IgG1-PE) and similarly amplified to control for background staining. 13 
Specificity of the anti-OSMR antibody was confirmed by siRNA knockdown of OSMR 14 
expression in a prior publication65. 15 
 16 
Immunohistochemistry. Formalin-fixed paraffin-embedded tissues were sectioned at five 17 
microns and collected onto Superfrost glass slides. Tissue sections were dewaxed in xylene and 18 
rehydrated through graded alcohol to water. Endogenous peroxidase activity was blocked with 19 
3% (v/v) hydrogen peroxide before masked antigens were retrieved by microwaving the tissue 20 
sections in target retrieval solution (Dako). Endogenous avidin and biotin were blocked (Vector 21 
Laboratories) and the tissue sections blocked with 10% (v/v) normal horse serum (Sigma 22 
Aldrich). Human tissue sections were incubated overnight at 4°C in a humidified environment 23 
with monoclonal mouse anti-PDPN antibody (Clone D2-40; Dako). Primary labelling was 24 
detected using biotinylated horse anti-mouse IgG secondary antibody (Vector Laboratories). 25 
Tissue sections were then incubated with streptavidin-horseradish peroxidase (Vector 26 
 24 
Laboratories) and signal detected using diaminobenzidine (Vector Laboratories). Tissue sections 1 
were counterstained with Mayer’s Haematoxylin (Sigma Aldrich) before being dehydrated 2 
through graded alcohol to xylene and mounted with DPX and coverslips applied. Mouse tissues 3 
were embedded into paraffin wax, sectioned, and antigens unmasked as above. Tissue sections 4 
were labelled with APC-conjugated hamster anti-mouse PDPN (clone 8.1.1; Biolegend) or APC-5 
conjugated IgG isotype control, before being counterstained with Hoechst 33258 and mounted in 6 
N-propyl gallate in glycerol-PBS. Images were collected on an Olympus BX51 microscope. 7 
PDPN was chosen as a stromal marker for immunohistochemistry for several reasons, including 8 
(a) anti-PDPN antibodies display excellent signal to noise ratio on formalin-fixed tissue sections; 9 
(b) PDPN staining is clearly specific for stromal and lymphatic endothelial cells in mouse and 10 
human based on flow cytometry analysis; and (c) the immunohistochemical performance of anti-11 
PDPN staining can be easily confirmed by observing staining of endothelial vessels. 12 
 For detection of mouse CD3, B220, and F4/80, tissue samples were fixed in formalin and 13 
embedded in paraffin. Paraffin sections were dewaxed and stained with hematoxylin and eosin 14 
(H&E) for overview. For immunohistochemistry, the sections were incubated with anti-B220 15 
(clone RA3-6B2, eBioscience) followed by incubation with secondary antibody (rabbit anti-rat, 16 
Dako). For detection, EnVision+ System-HRP Labelled Polymer Anti-Rabbit (Dako) was used. 17 
HRP was visualized with the chromogen diaminobenzidine (Dako). After color development, 18 
sections were subjected to a heat-induced epitope retrieval step prior to incubation with anti-19 
CD3ε antibody (clone M-20, Santa Cruz) followed by incubation with biotinylated secondary 20 
antibody (Dianova). For detection, alkaline phosphatase-labelled streptavidin and chromogen 21 
RED (both Dako) were employed. For the detection of macrophages, sections were subjected to 22 
protein-induced epitope retrieval employing protease (Sigma) prior to incubation with anti-F4/80 23 
(clone BM8, eBioscience) followed by incubation with biotinylated rabbit anti-rat secondary 24 
antibody  (Dako). Biotin was detected using alkaline phosphatase-labelled streptavidin (Dako). 25 
For visualization of alkaline phosphatase, chromogen RED (Dako) was used. Negative controls 26 
 25 
were performed by omitting the primary antibody, and nuclei were stained with hematoxylin. 1 
Sections were coverslipped with glycerol gelatin (Merck). 2 
 3 
Osmr detection by in situ hybridization. For detection of mouse Osmr mRNA, the RNAScope® 4 
2.5 HD Reagent Kit-RED (ACD Europe SRL) was used. Briefly, paraffin sections were freshly 5 
cut, dried for 1 hour at 60°C and dewaxed prior to mild unmasking with Target Retrieval buffer 6 
and protease. Pretreated sections were hybridized with specific probes to Omsr and Ppib (positive 7 
control) and irrelevant probe to dapb as a negative control. These were accompanied by an 8 
additional slide with formalin-fixed and paraffin embedded 3T3 cell line as an additional positive 9 
control. After hybridization signal amplification, binding of probes was visualized using FastRed. 10 
Nuclei were stained with hematoxylin and sections were coverslipped with Ecomount. 11 
Images were acquired using the AxioImager Z1 microscope (Carl Zeiss MicroImaging). All 12 
evaluations were performed in a blinded manner. 13 
 14 
Total protein extraction and immunoblot analysis. Total protein extracts were prepared as 15 
described66. Equal protein amounts were resolved by SDS-PAGE and analyzed with anti-p-16 
STAT3 (D3A7), anti-p-STAT1 (D4A7), anti-p-ERK1/2 (D13.14.4E), anti-p-AKT (D9E), anti-p-17 
p38 (D3F9), and anti-β-actin (13E5). All antibodies were from Cell Signaling, UK.  18 
 19 
Statistical analysis. Unless otherwise indicated, all bar charts represent means +/– S.E.M. 20 
Parametric and non-parametric analyses were used where appropriate based on testing for a 21 
normal distribution using the D’Agostino-Pearson Omnibus normality test. Statistical tests were 22 
two-sided and specified in figure legends. Differences were considered to be significant when 23 
p<0.05. Multiple testing corrections were applied where appropriate. In rare situations, data 24 
points were excluded from analysis only if they were found to be outliers using the ROUT 25 
method at Q=1% (pre-determined criteria).   26 
 26 
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Figure Legends  1 
 2 
Figure 1. Expression of OSM and OSMR in the inflamed intestinal tissue of patients with 3 
IBD. (a) Identification of cytokines associated with intestinal inflammation in CD and UC 4 
patients. Data were derived from Gene Expression Omnibus (GEO) datasets GSE57945 (n=42 5 
controls and n=162 CD) and GSE59071 (n=11 controls and n=74 UC). Briefly, mRNA 6 
expression of 64 cytokines was compared in IBD versus healthy control intestinal tissue using t-7 
tests with false discovery rate correction (Q=1%). Significant hits were further selected using a 8 
fold difference threshold of ≥2. (b) RNA sequencing analysis of 64 cytokine genes in pediatric 9 
treatment-naïve CD patients (n=162) versus non-IBD controls (n=42; GEO #GSE57945). Blue 10 
symbols, not statistically significant after t-tests with FDR correction (Q=1%); red symbols, 11 
significantly altered cytokines. (c) Expression of OSM, OSMR, LIFR, and IL6ST (gp130) in the 12 
GSE57945 dataset. Statistics: one-way ANOVA with Tukey’s multiple comparisons tests 13 
(df=201). (d–f) Q-PCR analysis of OSM and OSMR in intestinal mucosal biopsies from IBD 14 
patients and healthy controls (Oxford cohort, see Supplementary Table 3 for details). (d) 15 
Specimens categorized by macroscopic evidence of disease activity determined during endoscopy 16 
(includes IBD patients with no macroscopic inflammation (uninflamed), uninflamed specimens 17 
from patients with inflammation elsewhere in the bowel (uninvolved), and macroscopically 18 
inflamed specimens (lesional tissue)). Statistics: one-way ANOVA with Tukey’s multiple 19 
comparisons tests (df=88). (e) Samples categorized by inflammation severity, determined by 20 
routine clinical histopathological assessment of matched biopsies. Statistics: one-way ANOVA 21 
with Tukey’s multiple comparisons tests (df=74). (f) Analysis of inflamed lesions from active CD 22 
or UC.  23 
 24 
Figure 2. Association of OSM with response to anti-TNF therapy. (a) Identification of an 25 
OSM-associated inflammatory module in IBD. Expression of genes encoding chemokines and 26 
 28 
cytokines was examined in two cohorts, including healthy controls and patients with CD or UC 1 
(see Supplementary Fig. 2). Samples were grouped using unsupervised hierarchical clustering and 2 
21 genes that correlated closely with OSM in both cohorts were identified. (b) Unsupervised 3 
hierarchical clustering of OSM-associated module genes in colonic biopsies of UC patients 4 
refractory to corticosteroids or immunosuppression prior to infliximab therapy (GEO 5 
#GSE12251). Patients form two groups after clustering: one with low (blue dendrogram) and one 6 
with high OSM-associated module expression (red dendrogram). Patients with complete 7 
histological and endoscopic disease resolution are indicated in white, while treatment-refractory 8 
patients are indicated in black (see bar below dendrograms). Data are median-normalized and log2 9 
transformed. Rates of infliximab response in these patients are shown in panel (c). Statistics: 10 
Fisher’s exact test. (d) Receiver operator characteristic analysis of OSM and OSMR expression, 11 
distinguishing infliximab responders and non-responders in the GSE12251 dataset. (e–g) An 12 
independent cohort of patients with moderate-to-severe UC treated with infliximab as part of a 13 
long-term safety study (clinical trial NCT00207688). (e and f) Mayo scores and colonic OSM 14 
expression at baseline and 8 weeks after therapy in different response groups (see Methods for 15 
definition of clinical response). (g) Pearson correlation of baseline OSM expression and Mayo 16 
score. 17 
 18 
Figure 3. Non-hematopoietic stromal cells are prevalent in inflamed intestinal tissue and 19 
express high levels of OSMR. (a) Spearman correlation of OSMR expression with stromal genes 20 
in pooled healthy control and IBD biopsies assessed by Q-PCR (Oxford cohort, n=73). (b) Mean 21 
mRNA z-scores for the indicated stromal genes (top) and stromal signature expression (bottom) 22 
in intestinal biopsies from healthy controls or IBD patients (uninflamed, no endoscopic evidence 23 
of disease; uninvolved, uninflamed samples from patients with active disease; inflamed, samples 24 
from inflamed lesions). The stromal signature was calculated as the average log2 expression of 25 
COL1A1, FAP, ICAM1, and PDPN. Statistics: one-way ANOVA with Tukey’s multiple 26 
 29 
comparisons tests (DF=69). (c) Immunohistochemical staining of PDPN in colon tissue from 1 
representative non-IBD control, CD, and UC patients (scale bar=250µm). (d–f) Flow cytometry 2 
analysis of surgically resected human intestinal mucosa (n=11 donors). (d) Identification of 3 
leukocytes, epithelial cells, endothelial cells, and stroma. (e) OSMR expression and isotype-4 
normalized geometric mean fluorescence intensity (gMFI). Mean (+/− s.e.m.) gMFI of 5 
endothelial and stromal cells was compared using t-tests (t=3.924, df=20). (f) OSMR expression 6 
frequencies. (g) Cropped Western blot images of cytokine-stimulated (10 ng/ml, 20 minutes) 7 
CCD18Co cell lysates. (h) OSMR expression frequencies in colon mucosal cell populations from 8 
non-IBD controls or patients with IBD. (i) Intensity of OSMR expression on colon endothelial 9 
and stromal cells from non-IBD controls or patients with IBD. (j) Representative flow cytometry 10 
staining of OSMR, ICAM-1, and PDPN on colon stroma, with ICAM-1 and PDPN gMFIs 11 
quantified below. Statistics: Mann-Whitney U tests (n=11).  12 
 13 
Figure 4. OSM promotes inflammatory behavior in human intestinal stroma. (a) Q-PCR 14 
analysis of OSM-induced genes in triplicate cultures of CCD18Co cells (normal human colonic 15 
stroma), relative to untreated conditions. Results are representative of three independent 16 
experiments. (b–c) Analysis of OSMRlow and OSMRhigh stromal cells purified from resected 17 
human intestinal tissue using fluorescence-activated cell sorting (FACS). (b) Post-sorting cell 18 
purities from a representative non-IBD control. (c) Q-PCR analysis of stromal and inflammatory 19 
genes in the purified stromal fractions from n=3 donors. (d) Q-PCR analysis of triplicate 20 
CCD18Co cultures (representative of three independent experiments). Cells were stimulated with 21 
human OSM, TNF, IL-6, or combinations of the three for 2 hours and compared to untreated 22 
controls. Statistics: one-way ANOVA with Dunnett’s multiple comparisons tests (df=14). (e) Q-23 
PCR analysis of primary intestinal stromal cultures from 10 donors, stimulated as in panel (d). 24 
Data represent fold changes between matched untreated and cytokine-stimulated samples. 25 
Statistics: Wilcoxon signed rank test, versus a theoretical median of 1. (f) Q-PCR analysis of 26 
 30 
CXCL9 and CCL2 expression in cytokine-stimulated stromal cultures from non-IBD controls 1 
(n=7) and IBD patients (n=3). Data represent fold changes between matched untreated and 2 
cytokine-stimulated samples. Statistics: .t-tests (df=8). For CXCL9, t=3.594 (OSM), t=3.493 3 
(TNF), and t=8.278 (OSM+TNF). For CCL2, t=1.928 (OSM), t=3.940 (TNF), and t=4.87 4 
(OSM+TNF).  5 
 6 
Figure 5. The OSM-stromal cell axis is conserved in anti-TNF refractory murine colitis. (a) 7 
Induction of colitis using the Hh+αIL-10R protocol. Mice are sacrificed at day 14 or day 21, 8 
which corresponds to peak disease severity. (b) Total live CD45+ cells in the colon lamina propria 9 
at day 14 (n=8 steady state and n=9 colitic mice, representative of >3 independent experiments). 10 
(c) Q-PCR analysis of Osm and Osmr expression in whole-colon tissue from steady state (n=8) 11 
and colitic mice (n=15), representative of >3 independent experiments. (d) OSM measured by 12 
ELISA in colon explant supernatants and cecal stool extracts from one of two independent 13 
experiments (steady state n=4, colitis n=10). (e) Q-PCR gene expression analysis of FACS-14 
purified populations from mouse colon (representative of two independent experiments). Each 15 
data point represents lamina propria cells pooled from two mice. Stromal cells were defined as 16 
CD45–EpCAM–CD31–. (f) Immunofluorescent detection of PDPN+ stromal cells in healthy and 17 
inflamed mouse colon tissue. Scale bars, 250 µm (left) and 100 µm (right). (g) Detection of Osmr 18 
expression in healthy and inflamed mouse colon tissue using in situ hybridization (punctate red 19 
signal). Tissues were counterstained with hematoxylin. Examples of Osmr-expressing cells in 20 
healthy tissue are indicated with arrowheads. Scale bars, 250 µm (top) and 100 µm (bottom). 21 
PDPN and Osmr images are representative of 3 different mice per condition.  22 
 23 
Figure 6. OSM promotes anti-TNF refractory colitis in vivo. (a–d) Hh+αIL‑10R colitis in 24 
wild type C57BL/6 mice and Osm−/− littermates. (a) Representative colonoscopy images at day 25 
 31 
21, with endoscopic pathology scores shown in panel b. Data represent one of three independent 1 
experiments. (c) Representative H&E stained mid-colon cross-sections of healthy mice and colitic 2 
animals (day 21). Single arrows, crypt abscesses; double-arrows, submucosal edema. Scale bars: 3 
500µm (steady state) and 250µm (colitic). (d) Overall histopathology scores and sub-scores for 4 
days 14 and 21. n≥7 mice per time-point, pooled from three experiments. P-values reflect 5 
differences between genotypes and are derived from two-way ANOVA. (e) Expression of 6 
cytokine and chemokine genes in whole colon tissue from mice subjected to Hh+αIL‑10R colitis 7 
for 4, 9, or 14 days (n=4–6 per group). Expression values were averaged for mice within each 8 
genotype and timepoint group, and converted to z-scores. (f) Therapeutic blockade of OSM in the 9 
Hh+αIL‑10R model. OR-Fc (150 µg every two days) or a molar-equivalent dose of Fc control 10 
protein were injected intraperitoneally starting at day 7. (g, h) Representative H&E stained mid-11 
colon cross-sections of OR-Fc or Fc treated mice and associated histopathology scores (n=5–13 12 
mice per group, pooled from three experiments). P-values reflect differences between treatments 13 
and are derived from two-way ANOVA. Single arrows, crypt abscesses; double-arrows, 14 
submucosal edema and inflammatory infiltrate. Scale bar=250 µm. (i) Expression of the OSM-15 
associated inflammatory module in colons of mice treated as depicted in panel f. Data represent 16 
one of three independent experiments. 17 
 18 
 19 
  20 
 32 
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